Evidence map›Paper›PMID 25810538›Full record

ArticleJournal of virology2015

Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.

Nicola Ternette, Peter D Block, Álvaro Sánchez-Bernabéu, Nicola Borthwick, Elisa Pappalardo, Sultan Abdul-Jawad, Beatrice Ondondo, Philip D Charles, Lucy Dorrell, Benedikt M Kessler and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Slice-PASEF: Maximising Ion Utilisation in LC-MS Proteomics.bioRxiv : the preprint server for biology · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Vaccines · 2020
    Article
  10. Article
  11. Article
  12. Direct Detection and Quantification of Neoantigens.Cancer immunology research · 2019
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Nicola TernetteThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom nicola.ternette@ndm.ox.ac.uk.ORCID http://orcid.org/0000-0002-9283-0743
Peter D BlockThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Álvaro Sánchez-BernabéuTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom Universitat de Barcelona, Barcelona, Spain.
Nicola BorthwickThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Elisa PappalardoSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Sultan Abdul-JawadThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Beatrice OndondoThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Philip D CharlesTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Lucy DorrellThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Benedikt M KesslerTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Tomáš HankeThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
University of Oxford · GB

Funding

Medical Research Council G1001757Medical Research Council MC_U137884179Medical Research Council MRC G1001757
6 · The paper itself

Abstract

unlabelledCytotoxic T cells substantially contribute to the control of intracellular pathogens such as human immunodeficiency virus type 1 (HIV-1). Here, we evaluated the immunopeptidome of Jurkat cells infected with the vaccine candidate MVA.HIVconsv, which delivers HIV-1 conserved antigenic regions by using modified vaccinia virus Ankara (MVA). We employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify 6,358 unique peptides associated with the class I human leukocyte antigen (HLA), of which 98 peptides were derived from the MVA vector and 7 were derived from the HIVconsv immunogen. Human vaccine recipients responded to the peptide sequences identified by LC-MS/MS. Peptides derived from the conserved HIV-1 regions were readily detected as early as 1.5 h after MVA.HIVconsv infection. Four of the seven conserved peptides were monitored between 0 and 3.5 h of infection by using quantitative mass spectrometry (Q-MS), and their abundance in HLA class I associations reflected levels of the whole HIVconsv protein in the cell. While immunopeptides delivered by the incoming MVA vector proteins could be detected, all early HIVconsv-derived immunopeptides were likely synthesized de novo. MVA.HIVconsv infection generally altered the composition of HLA class I-associated human (self) peptides, but these changes corresponded only partially to changes in the whole cell host protein abundance. IMPORTANCE: The vast changes in cellular antigen presentation after infection of cells with a vectored vaccine, as shown here for MVA.HIVconsv, highlight the complexity of factors that need to be considered for efficient antigen delivery and presentation. Identification and quantitation of HLA class I-associated peptides by Q-MS will not only find broad application in T-cell epitope discovery but also inform vaccine design and allow evaluation of efficient epitope presentation using different delivery strategies.

Indexed as

AIDS VaccinesAntigens, ViralChromatography, LiquidGenetic VectorsHistocompatibility Antigens Class IHIV-1HumansJurkat CellsPeptidesTandem Mass SpectrometryTime FactorsT-Lymphocytes, CytotoxicVaccines, SyntheticVaccinia virusAIDS VaccinesAntigens, ViralHistocompatibility Antigens Class IPeptidesVaccines, Synthetic

Identifiers

PMID25810538
PMCPMC4442425
OpenAlexW2095893844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.